公开(公告)号：US09702877B2

公开(公告)日：2017-07-11

申请号：US12472319

申请日：2009-05-26

Applicant: Maher Albitar

Inventor： Maher Albitar

IPC: C12Q1/68 ,  C12P19/34 ,  G01N33/574 ,  A61K31/497 ,  A61K31/506 ,  C07K14/82

CPC classification number: G01N33/57426 ,  A61K31/497 ,  A61K31/506 ,  C07K14/82 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  A61K2300/00

Abstract: A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct. Also provided are methods compositions and kits for detecting the BCR-ABL splice variant. Additionally, methods for screening BCR-ABL kinase domain inhibitors which rely on the recombinant cells and methods of predicting likelihood for resistance of a CML patient with a BCR/ABL translocation respond to treatment with one or more BCR-ABL kinase inhibitors are also disclosed.

公开(公告)号：US09702010B2

公开(公告)日：2017-07-11

申请号：US14175676

申请日：2014-02-07

Applicant: YALE UNIVERSITY

Inventor： Alessandro D. Santin

IPC: A61K38/00 ,  C12Q1/68 ,  A61K38/16 ,  A61K38/48 ,  A61K39/395 ,  A61K45/06 ,  C07K16/30 ,  A61K39/00

CPC classification number: C12Q1/6886 ,  A61K38/164 ,  A61K38/4886 ,  A61K39/395 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/30 ,  C12Q2600/136 ,  C12Q2600/158 ,  A61K2300/00

Abstract: The invention discloses high levels of receptors for Clostridium perfringens enterotoxin (CPE) have been found in ovarian cancer and uterine cancer tissue samples. In addition, successful in vivo treatment of a mouse model of ovarian cancer with intraperitoneal injection of CPE is disclosed. High levels of Ep-CAM protein is also disclosed in ovarian cancer tissue samples. Thus, the invention provides a method of treating ovarian cancer and uterine cancer by administering CPE. The invention also provides a method of treating cancer in a mammal involving intraperitoneal administration of CPE, where at least some cancerous cells are located in or adjacent to the peritoneal cavity of the mammal. The invention also provides a method of treating ovarian cancer involving administering an anti-Ep-CAM antibody. The invention also provides a method of treating cancers expressing claudin-3 or claudin-4 by administering an antibody against claudin-3 and/or an antibody against claudin-4. The invention also provides a method of protecting a mammal from CPE toxicity involving administering a protective agent that binds to claudin-3 and/or claudin-4 and inhibits CPE binding to claudin-3 and/or claudin-4.

公开(公告)号：US20170189411A9

公开(公告)日：2017-07-06

申请号：US15247256

申请日：2016-08-25

Applicant: vTv Therapeutics LLC

Inventor： Jareer Nabeel Kassis ,  Otis Clinton Attucks ,  Matthew J. Kostura

IPC: A61K31/56 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/428

CPC classification number: A61K31/56 ,  A61K31/426 ,  A61K31/427 ,  A61K31/428 ,  A61K31/4709 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158

Abstract: The present invention provides methods of identifying compounds that selectively induce an oxidative stress response in a biological sample. The present invention further provides methods of treating a subject having a disease associated with oxidative stress using compounds that selectively induce an oxidative stress response in the subject. The invention further provides methods of selectively inducing an oxidative stress response in a cell.

公开(公告)号：US09695475B2

公开(公告)日：2017-07-04

申请号：US14651344

申请日：2013-12-11

Applicant: Ionis Pharmaceuticals, Inc.

Inventor： Xue-hai Liang ,  Stanley T. Crooke

IPC: C07H21/02 ,  C07H21/04 ,  C12Q1/68 ,  A61K31/7088 ,  A61K31/7115 ,  A61K31/712 ,  A61K31/7125 ,  A61K31/713 ,  C12N15/11 ,  C12N15/113

CPC classification number: C12Q1/6876 ,  A61K31/7088 ,  A61K31/7115 ,  A61K31/712 ,  A61K31/7125 ,  A61K31/713 ,  C12N15/111 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2320/11 ,  C12Q2600/136 ,  C12Q2600/178

Abstract: The present invention provides compounds and methods for competitive modulation of microRNAs. Such compounds and methods have profound effects on cells. MicroRNAs (microRNAs), are small (approximately 18-24 nucleotides in length), non-coding RNA molecules encoded in the genomes of plants and animals. In certain instances, microRNAs regulate the expression of genes by binding to the 3′-untranslated regions (3′-UTR) of specific mRNAs. More than 1000 different microRNAs have been identified in plants and animals.

公开(公告)号：US20170184600A1

公开(公告)日：2017-06-29

申请号：US15232048

申请日：2016-08-09

Applicant: Children's Medical Center Corporation

Inventor： BRUCE R. ZETTER ,  Lere Bao ,  Jacqueline Banyard

IPC: G01N33/574 ,  C07K16/30 ,  C12Q1/68

CPC classification number: G01N33/57484 ,  C07K16/3015 ,  C07K16/303 ,  C07K16/3046 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/622 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  G01N33/57415 ,  G01N33/57426 ,  G01N33/57434 ,  G01N33/57438 ,  G01N33/6887 ,  G01N2333/78

Abstract: We have discovered a protein in humans, herein referred to as collagen like gene (CLG) product (SEQ ID NOS: 12 and 13), that is expressed in human prostate cancer and breast cancer cell lines but not in normal adult, placenta, lung, liver, skeletal muscle, kidney or pancreas tissues. We have also discovered that the level of CLG mRNA expression correlates positively with the metastatic potential of the cancer cell lines tested.

公开(公告)号：US20170184565A1

公开(公告)日：2017-06-29

申请号：US15116319

申请日：2015-02-12

Applicant: Thomas M. ROBERTS ,  Haoxuan TONG ,  Jean J. ZHAO ,  John BLENIS ,  Dana-Farber Cancer Institute, Inc. ,  PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： Thomas M. Roberts ,  Haoxuan Tong ,  Jean Zhao ,  John Blenis

IPC: G01N33/50 ,  A61K45/06 ,  A61K31/58 ,  G01N33/574 ,  C12Q1/68

CPC classification number: G01N33/5011 ,  A61K31/58 ,  A61K45/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/5088 ,  G01N33/57492 ,  G01N2333/91215 ,  G01N2500/10

Abstract: The present invention is based, in part, on the identification of novel FI.3K-mTORCI-S6K 1 signaling pathway biomarkers predictive of responsiveness to anti-cancer therapies.

公开(公告)号：US09689879B2

公开(公告)日：2017-06-27

申请号：US15252938

申请日：2016-08-31

Applicant: EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH

Inventor： Dragan Grabulovski ,  Dario Neri

IPC: G01N33/68 ,  C40B30/04

CPC classification number: G01N33/6845 ,  C12Q1/485 ,  C12Q2600/136 ,  G01N2333/912 ,  G01N2333/91205 ,  G01N2500/00 ,  G01N2500/04 ,  G01N2500/20

Abstract: The present invention relates to a method for the production of a library comprising recombinant derivatives of the SH3 domain of the Fyn kinase of SEQ ID NO: 1 as well as a method for selecting from a library comprising recombinant derivatives of the SH3 domain of the Fyn kinase of SEQ ID NO: 1 one or more of said derivatives having a specific binding affinity to a protein or peptide.

公开(公告)号：US20170153257A1

公开(公告)日：2017-06-01

申请号：US15289946

申请日：2016-10-10

Applicant: DiCE Molecules SV, LLC

Inventor： Phillip Patten ,  Pehr Harbury ,  Donald Schmidt ,  Martin Linsell ,  Kenneth Wlasichuk ,  Robin Prince ,  Timothy J. Church ,  Wouter Van der Linden

IPC: G01N33/92 ,  G01N33/68 ,  B01D15/32 ,  G01N30/02 ,  G01N33/15 ,  C12Q1/68 ,  C07H21/04

CPC classification number: G01N33/92 ,  B01D15/325 ,  C07H21/04 ,  C12Q1/68 ,  C12Q1/6804 ,  C12Q1/6876 ,  C12Q2600/136 ,  G01N30/02 ,  G01N33/15 ,  G01N33/6803 ,  G01N2030/027 ,  C12Q2563/179 ,  C12Q2565/125 ,  C12Q2565/514 ,  C12Q2565/119 ,  C12Q2565/137

Abstract: Disclosed herein are methods of estimating LogD of compounds comprising a ligand operatively linked to a recognition element. The methods generally involve contacting the compounds with a matrix, measuring the interaction of the compounds with the matrix and relating the interaction of the compounds with the matrix to LogD of the compounds. Also, described herein, are novel compounds which include a ligand operatively linked to a recognition element and linkers that connect the ligand to the recognition element.

公开(公告)号：US20170153240A1

公开(公告)日：2017-06-01

申请号：US15363456

申请日：2016-11-29

Applicant: SUNGKWANG MEDICAL FOUNDATION

Inventor： Hee Jung AN ,  Ah Young KWON

IPC: G01N33/574 ,  C12Q1/68 ,  C12N15/113

CPC classification number: G01N33/57449 ,  C12N15/113 ,  C12N2310/14 ,  C12N2320/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2333/4703

Abstract: Provided are a composition, a kit, and a method of predicting prognosis of ovarian cancer or a risk of recurrence of ovarian cancer. Provided are a composition for treating ovarian cancer or preventing recurrence of ovarian cancer and a method of screening a material for treating ovarian cancer or preventing recurrence of ovarian cancer. According to the present disclosure, prognosis or recurrence of ovarian cancer can be efficiently diagnosed, and a candidate material that can treat ovarian cancer or prevent recurrence of ovarian cancer can be efficiently screened.

公开(公告)号：US20170152570A1

公开(公告)日：2017-06-01

申请号：US15346671

申请日：2016-11-08

Applicant: DNA-SEQ, INC.

Inventor： Janusz Sowadski ,  Davide Moiani

IPC: C12Q1/68 ,  G06F19/28 ,  G06F19/22 ,  G06F19/16 ,  G06F19/24

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/156 ,  C40B30/04 ,  G16B15/00 ,  G16B30/00 ,  G16B40/00 ,  G16B50/00 ,  G16C20/30

Abstract: The present invention relates to the discovery of a method for identifying a treatment regimen for a patient diagnosed with cancer, predicting patient resistance to therapeutic agents and identifying new therapeutic agents. Specifically, the present invention relates to the use of an algorithm to identify a mutation in a kinase, determine if the mutation is an activation or resistance mutation and then to suggest an appropriate therapeutic regimen. The invention also relates to the use of a pattern matching algorithm and a crystal structure library to predict the functionality of a gene mutation, predict the specificity of small molecule kinase inhibitors and for the identification of new therapeutic agents.